Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.34 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.31 |
| ▸ | STK4 | Q13043 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24692385 | 0.94 | KRAS (0.40) | KRASNTRK1MAP4K1 | |
| SCHEMBL24692398 | 0.88 | KRAS (0.40) | KRAS | |
| SCHEMBL25830219 | 0.85 | KRAS (0.46) | KRAS | |
| SCHEMBL25830213 | 0.83 | KRAS (0.37) | KRASNTRK1MAP4K1 | |
| SCHEMBL30725828 | 0.82 | KRAS (0.44) | KRAS | |
| SCHEMBL25848667 | 0.80 | KRAS (0.38) | KRAS | |
| SCHEMBL24692782 | 0.79 | KRAS (0.51) | KRAS | |
| SCHEMBL23137565 | 0.79 | KRAS (0.51) | KRAS | |
| SCHEMBL24692109 | 0.79 | KRAS (0.46) | KRAS | |
| SCHEMBL27137923 | 0.79 | KRAS (0.46) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | KRAS 1/4885NTRK1 699/4885MAP4K1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.